Abstract 446P
Background
Patients with cancer often develop cachexia. There has been no clearly effective treatment for this condition. However, anamorelin is approved for the treatment of cancer cachexia associated with advanced non-small cell lung cancer.
Methods
We conducted a retrospective analysis of treatment efficacy, adverse events and background factors in non-small cell lung cancer patients treated with anamorelin for cancer cachexia at our hospital from 1 April 2021 to 30 April 2023. Anamorelin effective cases were defined as those with improved performance status (PS) or appetite.
Results
A total of 68 patients were treated with anamorelin during the study period. The median age was 76.5 (59-92) years and the male patients were predominantly. Comorbidities included COPD (29.4%), interstitial pneumonia (22.1%). The clinical stage of lung cancer was stage 4 in 75.7% of patients. The median duration of anamorelin treatment was 36 (1-714) days. Anamorelin improved anorexia in 32 patients and PS in 21 patients. According to the definition of our study, there were 34 patients with anamorelin response and 34 patients without response. The patients with anamorelin response had a significantly longer duration of treatment (P<0.01) and significantly lower C-reactive protein (CRP) before treatment (P=0.04) compared to the patients without anamorelin response. The most common adverse events were nausea (14.7%), appetite loss (13.2%), hyperglycemia (11.8%) and liver damage (10.3%), respectively. Three patients experienced G3≤ adverse events. Fourteen (20.6%) patients discontinued anamorelin due to adverse events. The frequency of adverse events did not differ between the two groups.
Conclusions
Anamorelin improved appetite or PS in half of the patients in this retrospective study. In contrast, 14 (20.6 %) patients discontinued treatment due to adverse events. Anamorelin may be more effective in patients with lower CRP levels prior to treatment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
T. Ito.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
497P - Sintilimab in combination with anlotinib in advanced NSCLC treated with first-line PD-1 antibodies: An open, single-arm, phase II trial
Presenter: Ying Jin
Session: Poster Display
Resources:
Abstract
498P - Frailty-adjusted life expectancy and survival in older lung cancer patients: A large-scale electronic health-record based study
Presenter: Thao Tu
Session: Poster Display
Resources:
Abstract
499P - Long-term survival and treatment (tx) patterns after first-line (1L) osimertinib in patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive (m) advanced non-small cell lung cancer (NSCLC): Japanese cohort of a global real-world (rw) observational study
Presenter: Daichi Fujimoto
Session: Poster Display
Resources:
Abstract
500P - The effectiveness and safety of durvalumab after chemoradiotherapy for locoregional recurrence of completely resected non-small cell lung cancer: Real-world, multicenter, observational study (NEJ056)
Presenter: Hidehito Horinouchi
Session: Poster Display
Resources:
Abstract
501P - One-year survival outcomes of unresectable stage III non-small cell lung cancer patients who underwent PD-1 inhibitor plus chemo as induction therapy
Presenter: Xin Wang
Session: Poster Display
Resources:
Abstract
502P - Impact of sarcopenia on the outcome of patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy followed by durvalumab
Presenter: Kentaro Tamura
Session: Poster Display
Resources:
Abstract
503P - Clinical outcomes by infusion timing of immune checkpoint inhibitors in patients with locally advanced NSCLC
Presenter: TSUYOSHI HIRATA
Session: Poster Display
Resources:
Abstract
504P - Real-world outcomes with induction systemic therapy for stage III in eligible for upfront local therapy: Pre vs post immunotherapy era in a tertiary referral centre
Presenter: Praveen Kumar Marimuthu
Session: Poster Display
Resources:
Abstract
505P - Neoadjuvant PD-1 inhibitor (tislelizumab) plus platinum–etoposide in patients with limited-stage small cell lung cancer: A phase II trial
Presenter: Junjie Hu
Session: Poster Display
Resources:
Abstract
506P - Intrathoracic progression is still the most dominant failure pattern after first-line chemo-immunotherapy in extensive-stage small-cell lung cancer: Implications for thoracic radiotherapy
Presenter: Byoung Hyuck Kim
Session: Poster Display
Resources:
Abstract